Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Pembrolizumab Studies Show Disparate Data on Link Between AE and Response in Multiple Myeloma

June 2nd 2018

Pembrolizumab (Keytruda) yielded inconsistent results regarding the relationship between immune-related adverse events and objective response in multiple myeloma.

Once Weekly Carfilzomib Superior in Relapsed/Refractory Myeloma

June 2nd 2018

Carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.

bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma

June 2nd 2018

bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.

Practice Changes for Use of Immunotherapy in NSCLC: Q&A

June 2nd 2018

Using Immunotherapy Beyond Progression in NSCLC

June 2nd 2018

Optimizing Immunotherapy in the NSCLC Treatment Paradigm

June 2nd 2018

Tumor Mutational Burden in NSCLC: Should it be Routine?

June 2nd 2018

Impact of Data on the Real-Life Treatment of NSCLC

June 2nd 2018

Important Data in the Squamous NSCLC Population

June 2nd 2018

IMPower150: Implications for the Treatment of NSCLC

June 2nd 2018

CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

June 2nd 2018

Actual Use of Pembrolizumab and Chemotherapy in NSCLC

June 2nd 2018

KEYNOTE Trial Data: Pembrolizumab's Role in NSCLC

June 2nd 2018

ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

June 2nd 2018

ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts

June 2nd 2018

ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma

June 2nd 2018

ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma

June 2nd 2018

ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer

June 2nd 2018